Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 12;7(17):4869-4873.
doi: 10.1182/bloodadvances.2023010480.

No sex differential in relative survival among older patients with DLBCL treated with R-CHOP21: a population-based study

Emma E Geerdes  1 , Müjde Durmaz  1   2 , Pieternella J Lugtenburg  3 , Martine E D Chamuleau  4 , Otto Visser  5 , Djamila E Issa  6 , Rolf E Brouwer  7 , Eduardus F M Posthuma  7   8 , Josée M Zijlstra  4 , Marie José Kersten  2 , Avinash G Dinmohamed  1   2   4   9
Affiliations

No sex differential in relative survival among older patients with DLBCL treated with R-CHOP21: a population-based study

Emma E Geerdes et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: M.J.K. reports honoraria and research funding from Roche to the institution, where she is employed. The remaining authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
The sex-specific relative survival (RS) of R-CHOP21-treated older (>60 years) patients with DLBCL in The Netherlands, from 2014 to 2020. Sex-specific RS is shown for the following age categories at diagnosis: (A) >60 years, (B) from 61 to 70 years, (C) from 71 to 80 years, and (D) >80 years. The tables present the projected 3- and 5-year RS with associated 95% confidence intervals and the number at risk according to sex. The P value is derived from the likelihood ratio test that compares the model with years of follow-up and sex with the model containing only years of follow-up. The median follow-up for 2115 (66%) patients alive at the end of follow-up was 47.3 months (interquartile range, 28.2-69.5 months). CI, confidence interval.
See this image and copyright information in PMC

References

    1. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–242. - PubMed
    1. Pfreundschuh M, Murawski N, Zeynalova S, et al. Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients. Br J Haematol. 2017;179(3):410–420. - PubMed
    1. Pfreundschuh M, Müller C, Zeynalova S, et al. Suboptimal dosing of rituximab in male and female patients with DLBCL. Blood. 2014;123(5):640–646. - PubMed
    1. Eyre TA, Martinez-Calle N, Hildyard C, et al. Male gender is an independent predictor for worse survival and relapse in a large, consecutive cohort of elderly DLBCL patients treated with R-CHOP. Br J Haematol. 2019;186(4):e94–e98. - PubMed
    1. Pfreundschuh M, Poeschel V, Zeynalova S, et al. Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group. J Clin Oncol. 2014;32(36):4127–4133. - PubMed

Substances